Leuprolide
- Generic Name
- Leuprolide
- Brand Names
- Camcevi, Eligard, Fensolvi, Lupaneta Pack 1-month, Lupron, Lupron Depot-ped, Viadur, Zeulide Depot
- Drug Type
- Small Molecule
- Chemical Formula
- C59H84N16O12
- CAS Number
- 53714-56-0
- Unique Ingredient Identifier
- EFY6W0M8TG
- Background
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the...
- Indication
Leuprolide is indicated for the treatment of advanced prostate cancer and as palliative treatment of advanced prostate cancer.
It is also used for the treatment of pediatric patients with central precocious puberty (CPP).
...
- Associated Conditions
- Advanced Prostate Cancer, Anemia, Central Precocious Puberty (CPP), Endometriosis
- Associated Therapies
- Palliative Treatment
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
- Conditions
- Interventions
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Emory University
- Target Recruit Count
- 72
- Registration Number
- NCT06650579
- Locations
- 🇺🇸
Emory Proton Therapy Center, Atlanta, Georgia, United States
🇺🇸Winship at Emory Midtown, Atlanta, Georgia, United States
🇺🇸Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer
- Conditions
- Interventions
- First Posted Date
- 2024-10-04
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Brazilian Clinical Research Institute
- Target Recruit Count
- 144
- Registration Number
- NCT06627530
Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial
- Conditions
- Interventions
- Drug: AbirateroneDrug: ApalutamideProcedure: Biospecimen CollectionProcedure: Bone ScanProcedure: Computed TomographyDrug: DarolutamideDrug: DegarelixDrug: EnzalutamideDrug: GoserelinDrug: HistrelinDrug: LeuprolideProcedure: Magnetic Resonance ImagingOther: Patient ObservationProcedure: Positron Emission TomographyDrug: PrednisoneOther: Questionnaire AdministrationDrug: RelugolixRadiation: Stereotactic Body Radiation TherapyDrug: Triptorelin
- First Posted Date
- 2024-04-23
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 120
- Registration Number
- NCT06378866
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2024-03-26
- Target Recruit Count
- 70
- Registration Number
- NCT06330805
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Adenomyosis and ART
- Conditions
- Interventions
- First Posted Date
- 2023-07-10
- Last Posted Date
- 2023-07-10
- Lead Sponsor
- Azienda Ospedaliero-Universitaria di Modena
- Target Recruit Count
- 500
- Registration Number
- NCT05937490
- Locations
- 🇮🇹
Azienda Ospedaliero-Universitaria di Modena, Modena, Italy
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 3100
- Registration Number
- NCT05827081
- Locations
- 🇦🇺
Novartis Investigative Site, Gateshead, New South Wales, Australia
RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
- Conditions
- Interventions
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 110
- Registration Number
- NCT05765500
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute at Foxborough, Foxboro, Massachusetts, United States
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
- Conditions
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT05701007
- Locations
- 🇫🇮
Pfizer, Helsinki, Finland
A Multicenter Open-label Clinical Study on the Prevention of Premature Ovarian Failure After HSCT
- Conditions
- Interventions
- First Posted Date
- 2022-12-28
- Last Posted Date
- 2023-02-23
- Target Recruit Count
- 200
- Registration Number
- NCT05667428
- Locations
- 🇨🇳
First Affiliated Hospital of Xian Jiaotong University, Xi'an, Shaanxi, China
A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease
- Conditions
- Interventions
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 36
- Registration Number
- NCT05478083
- Locations
- 🇳🇱
Groningen universitair medical center, Groningen, Netherlands
🇳🇱Radboudumc, Nijmegen, Gelderland, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.